Ask to take part

Contact the study team using the details below to take part. If there are no contact details below please ask your doctor in the first instance.

Contact Information:

Study Location:

Find another location


Questions to ask
Skip to Main Content
English | Cymraeg
Be Part of Research - Trial Details - Study of ASTX029 in Subjects With Advanced Solid Tumors
Back

Study of ASTX029 in Subjects With Advanced Solid Tumors

Not Recruiting

Open to: ALL

Age: 18.0 - N/A

Manchester Newcastle Upon Tyne Oxford Cambridge

Medical Conditions

Neoplasms

This information is provided directly by researchers, and we recognise that it isn't always easy to understand. We are working with researchers to improve the accessibility of this information. In some summaries, you may come across links to external websites. These websites will have more information to help you better understand the study.


This study is a first-in-human, open-label, multicenter, Phase 1-2 study to assess the safety, pharmacokinetics, pharmacodynamics, and preliminary clinical activity of ASTX029 administered orally to subjects with advanced solid malignancies who are not candidates for approved or available therapies.

Start dates may differ between countries and research sites. The research team are responsible for keeping the information up-to-date.  

The recruitment start and end dates are as follows:

May 2018 Aug 2024

Publications

"Munck JM, Berdini V, Bevan L, Brothwood JL, Castro J, Courtin A, East C, Ferraldeschi R, Heightman TD, Hindley CJ, Kucia-Tran J, Lyons JF, Martins V, Muench S, Murray CW, Norton D, O'Reilly M, Reader M, Rees DC, Rich SJ, Richardson CJ, Shah AD, Stanczuk L, Thompson NT, Wilsher NE, Woolford AJ, Wallis NG. ASTX029, a Novel Dual-mechanism ERK Inhibitor, Modulates Both the Phosphorylation and Catalytic Activity of ERK. Mol Cancer Ther. 2021 Oct;20(10):1757-1768. doi: 10.1158/1535-7163.MCT-20-0909. Epub 2021 Jul 30."; "34330842"

INTERVENTIONAL

Intervention Type : DRUG
Intervention Description : Described above

Intervention Arm Group : Phase 1 Regimen 1;Phase 1 Regimen 2;Phase 2;



You can take part if:



You may not be able to take part if:


This is in the inclusion criteria above


Below are the locations for where you can take part in the trial. Please note that not all sites may be open.

  • The Christie NHS Foundation Trust Site#220
    Manchester
    England
    M20 4BX
  • The Newcastle Upon Tyne Hospitals NHS Foundation Trust Site #221
    Newcastle Upon Tyne
    NE7 7DN
  • Churchill Hospital Site #224
    Oxford
    OX3 7LE
  • Cambridge University Hospitals NHS Foundation Trust
    Cambridge
    CB2 0QQ


The study is sponsored by Taiho Oncology, Inc.



We'd like your feedback

Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.


Is this study information helpful?

What will you do next?
Read full details for Trial ID: NCT03520075
Last updated 05 January 2025

This page is to help you find out about a research study and if you may be able to take part

You can print or share the study information with your GP/healthcare provider or contact the research team directly.   

Back to the top